Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Magnesium sulfate prophylaxis for cerebral vasospasm after traumatic subarachnoid hemorrhage
IRCT20221023056270N1Phase 3Completed
- Sponsor
- Tabriz University of Medical Sciences
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-blind trial of magnesium sulfate in subarachnoid hemorrhage (SAH) (2 arms), sponsored by Tabriz University of Medical Sciences. Primary endpoints: Cerebral vasospasm incidence and Clinical prognosis. Started Sep 2025; status: completed.
02
Drugs
magnesium sulfate
03
Conditions
subarachnoid hemorrhage (SAH)
Beyond the preview
Go deeper on IRCT20221023056270N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20221023056270N1.